Patents Assigned to PROTAB LTD.
  • HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF
    Publication number: 20140170138
    Abstract: The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
    Type: Application
    Filed: January 31, 2014
    Publication date: June 19, 2014
    Applicant: Protab Ltd.
    Inventors: Yaakov Naparstek, Shira Yair, Dorit LANDSTEIN
  • Humanized antibodies specific for HSP65-derived peptide-6 methods and uses thereof
    Patent number: 8680241
    Abstract: The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: March 25, 2014
    Assignee: Protab Ltd.
    Inventors: Yaakov Naparstek, Shira Yair
  • Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
    Patent number: 8642041
    Abstract: The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
    Type: Grant
    Filed: March 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Protab Ltd.
    Inventors: Yaakov Naparstek, Eli Moallem
  • HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF
    Publication number: 20120156201
    Abstract: The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
    Type: Application
    Filed: September 6, 2010
    Publication date: June 21, 2012
    Applicant: PROTAB LTD.
    Inventors: Yaakov Naparstek, Shira Yair
  • ADENYLYL CYCLASE-ASSOCIATED PROTEIN (CAP1) AND USES THEREOF AS A TARGET FOR IMMUNO-MODULATION
    Publication number: 20120014973
    Abstract: The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.
    Type: Application
    Filed: March 21, 2010
    Publication date: January 19, 2012
    Applicant: PROTAB LTD.
    Inventors: Yaakov Naparstek, Eli Moallem